{
  "drug_name": "Glycoprotein_IIB/IIIA_inhibitor",
  "url": "https://wikem.org/wiki/Glycoprotein_IIB/IIIA_inhibitor",
  "scraped_at": "2026-01-10T07:54:00.852604",
  "sections": {
    "Background": {
      "text": "By competing with fibrinogen and von Willebrand factor (vWF) for GP IIb/IIIa binding, GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation\nMostly indicated for patients undergoing PCI for\nACS",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "ACS",
          "url": "https://wikem.org/wiki/ACS"
        }
      ]
    },
    "Glycoprotein_IIB/IIIA_inhibitors": {
      "text": "Abciximab\n(ReoPro)\nEptifibatide\n(Integrilin)\nTirofiban\n(Aggrastat)",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Abciximab",
          "url": "https://wikem.org/wiki/Abciximab"
        },
        {
          "text": "Eptifibatide",
          "url": "https://wikem.org/wiki/Eptifibatide"
        },
        {
          "text": "Tirofiban",
          "url": "https://wikem.org/wiki/Tirofiban"
        }
      ]
    }
  }
}